QC
ACRS icon

Quadrature Capital’s Aclaris Therapeutics ACRS Stock Holding History

Quadrature Capital’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$272K Buy
72,540
+14,870
+26% +$50.2K ﹤0.01% 1014
2025
Q4 		$174K Buy
57,670
+26,117
+83% +$66K ﹤0.01% 1001
2025
Q3 		$59.6K Sell
31,553
-6,697
-18% -$11.7K ﹤0.01% 943
2025
Q2 		$54.5K Sell
38,250
-1,081
-3% -$1.46K ﹤0.01% 939
2025
Q1 		$59.8K Buy
+39,331
New +$83.9K ﹤0.01% 966

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Quadrature Capital's ACRS Position: Q1 2026 in Review

Quadrature Capital increased its Aclaris Therapeutics (ACRS) stake by 26% in Q1 2026, buying an estimated $50.2K and bringing the position to 72,540 shares worth $272K. The position accounts for ﹤0.01% of the portfolio, ranked #1014.

Quadrature Capital first reported a position in ACRS in Q1 2025 and has held it in 5 quarters since. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Quadrature Capital held 72,540 shares of Aclaris Therapeutics worth $272K as of Q1 2026.
  • Quadrature Capital bought 14,870 Aclaris Therapeutics shares in Q1 2026, an estimated $50.2K.
  • Aclaris Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q1 2026, its #1014 holding.
  • Quadrature Capital first reported a position in Aclaris Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.